![]() |
市場調查報告書
商品編碼
1963955
非血壓監測儀市場-全球產業規模、佔有率、趨勢、機會、預測:按產品類型、最終用戶、地區和競爭對手分類,2021-2031年Cuffless Blood Pressure Monitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End User, By Region & Competition, 2021-2031F |
||||||
全球無袖帶血壓監測儀市場預計將從 2025 年的 16.9 億美元成長到 2031 年的 29.3 億美元,複合年成長率為 9.61%。
這些非侵入式設備利用光電脈搏波檢測法和傳播時間分析等感測器技術來計算血壓指標,無需使用氣動袖套阻斷動脈。市場成長的主要促進因素是對持續遠端患者監護需求的不斷成長以及這些被動式系統帶來的便利性提升。全球慢性心血管疾病發生率的上升也大大推動了這一趨勢。根據世界衛生組織 (WHO) 估計,到 2024 年,全球約有 14 億成年人將患有高血壓,這表明對有效的長期管理工具的需求非常迫切。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 16.9億美元 |
| 市場規模:2031年 | 29.3億美元 |
| 複合年成長率:2026-2031年 | 9.61% |
| 成長最快的細分市場 | 腕戴式 |
| 最大的市場 | 北美洲 |
然而,該行業在臨床準確性和設備監管標準化方面面臨許多挑戰。為了獲得醫學界的支持,必須證明基於感測器的估計值能夠在廣泛的患者群體中可靠地達到與傳統聽診相當的準確性。衛生當局為防止誤診而製定的嚴格檢驗通訊協定進一步加劇了這一難度。因此,滿足嚴格的準確性標準是製造商必須克服的主要障礙,才能將這些設備從消費保健產品提升為公認的臨床設備。
全球高血壓和心血管疾病發生率的激增是推動全球無袖帶血壓監測市場發展的主要動力。隨著這些慢性疾病達到流行程度,間歇性、診所測量的限制日益凸顯,迫切需要連續、非侵入性的監測方式。近期統計數據也印證了這項迫切需求。根據 MedCloudInsider 於 2025 年 7 月發布的題為「FDA核准首款商用無袖帶血壓監測儀進入美國市場」的報告,目前美國近 50% 的成年人患有高血壓。如此高的盛行率促使人們轉向能夠在日常生活中追蹤血壓波動的設備,市場也正從阻塞式測量技術轉向被動式監測工具。
同時,穿戴式生物感測器和光學技術的突破性進展正在改變這一領域,將醫療級精度帶入消費級產品設計中。光電容積脈搏波描記法 (PPG) 和感測器融合技術的檢測法使得可靠的血壓估算功能得以整合到智慧型手錶和智慧戒指中,顯著提升了產品的實用性和普及度。這些創新技術的商業性潛力得到了大量資金籌措的支持。例如,Aktiia 在 2025 年 5 月的新聞稿中宣布,已籌集 4,200 萬美元,用於加速其光學血壓監測生態系統的全球部署。此外,這些進展也直接解決了使用者持續接受度的挑戰。根據 MedCloudInsider 2025 年的報告,臨床研究表明,91% 的未控制高血壓患者更傾向於使用無袖帶、智慧型手機連接的血壓監測系統,而不是傳統的監測方法。
阻礙市場發展的核心障礙在於對臨床準確性和監管標準的嚴格要求。儘管感測器技術不斷發展,但獲得醫療設備認證仍然是一項艱鉅的任務。醫療機構和監管機構要求強力的證據,證明這些設備在各種條件下都能提供與動脈內檢測法或標準聽診一樣精確的測量結果。在獲得這種檢驗之前,這些監測設備無法從消費級健康小工具轉變為適用於診斷和治療高血壓的合法醫療設備。
由於缺乏經認證的可靠性,這些血壓監測儀在臨床應用中受到極大限制。據美國心臟協會稱,到2025年,全球流通的血壓監測儀中約有80%缺乏正式檢驗測試的公開數據,而無袖帶血壓監測技術由於缺乏標準化的測試通訊協定,這一差距尤為顯著。因此,由於無法達到既定的準確性標準,這些產品難以獲得醫生的廣泛信任,實際上被排除在醫療市場的核心之外,並將收入潛力限制在監管較少的消費者醫療保健領域。
人工智慧的整合正在從根本上改變市場格局,它提高了光學感測器的訊號保真度,並使其達到醫療級標準。製造商正利用先進的機器學習演算法,從運動偽影和環境干擾中分離出純淨的光電脈搏波測量數據,從而解決無袖帶技術長期以來面臨的精度挑戰。這項技術進步凸顯了軟體驅動解決方案的有效性。例如,Binah.ai 在 2025 年 3 月發布的「SDK 5.9.1 血壓精度報告」中指出,其人工智慧增強的掃描技術在 87.9% 的收縮壓測量案例中達到了目標誤差範圍內的精度,證明了其適用於可靠的遠端健康評估。
同時,業界正明顯轉向智慧戒指和穿戴設備,認為它們是持續被動監測的最佳形式。與智慧型手錶相比,這些小巧的設備具有更佳的皮膚接觸性和佩戴舒適度,能夠在不干擾日常生活的情況下持續採集時間序列數據。主要產業參與者正積極研發符合監管規定的戒指式創新產品,加速這項轉變。根據 MedTech Dive 於 2025 年 10 月發表的報導《Oura 智慧戒指血壓測量功能申請 FDA 批准》報道,Oura Health 已核准啟動一項新功能的檢驗研究,該功能可檢測慢性高血壓的生理指標。這標誌著隱藏式戒指管理工具的商業化邁出了重要一步。
The Global Cuffless Blood Pressure Monitor Market is projected to expand from USD 1.69 Billion in 2025 to USD 2.93 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 9.61%. These non-invasive devices utilize sensor technologies, including photoplethysmography and transit time analysis, to calculate blood pressure metrics without the need for arterial occlusion via an inflatable cuff. Market growth is primarily driven by the rising demand for continuous remote patient monitoring and the enhanced convenience these passive systems provide. This trajectory is heavily supported by the increasing global incidence of chronic cardiovascular diseases; the World Health Organization estimated that in 2024, approximately 1.4 billion adults worldwide were affected by hypertension, underscoring the critical need for effective long-term management tools.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 1.69 Billion |
| Market Size 2031 | USD 2.93 Billion |
| CAGR 2026-2031 | 9.61% |
| Fastest Growing Segment | Wrist-Based |
| Largest Market | North America |
However, the industry encounters significant hurdles related to clinical accuracy and the regulatory standardization of these devices. Securing endorsement from the medical community necessitates demonstrating that sensor-based estimations can reliably match the precision of traditional auscultatory methods across a wide range of patient demographics. This difficulty is exacerbated by the stringent validation protocols mandated by health authorities to avoid misdiagnosis. As a result, meeting rigorous accuracy standards stands as a pivotal barrier that manufacturers must surmount to elevate these devices from consumer wellness items to accepted clinical instruments.
Market Driver
The surging global incidence of hypertension and cardiovascular diseases acts as the primary engine driving the global cuffless blood pressure monitor market. As these chronic conditions reach epidemic levels, the inadequacies of episodic, clinic-based readings have become increasingly evident, fueling an urgent requirement for continuous and unobtrusive monitoring capabilities. This pressing need is emphasized by recent statistics; a July 2025 report by MedCloudInsider, titled "FDA Clears First Over-the-Counter Cuffless Blood Pressure Monitor for U.S. Market," indicates that hypertension currently affects nearly 50% of the adult population in the United States. Such high prevalence mandates a transition toward devices capable of tracking blood pressure variability in everyday environments, steering the market away from occlusion-based techniques in favor of passive surveillance tools.
Concurrently, technological breakthroughs in wearable biosensors and optical methods are transforming the sector by facilitating medical-grade precision within consumer-friendly designs. Developments in photoplethysmography and sensor fusion have enabled the integration of dependable blood pressure estimation into smartwatches and rings, greatly improving utility and adoption rates. The commercial promise of these innovations is highlighted by significant financial backing; for instance, Aktiia announced in a May 2025 press release that it had raised $42 million to fast-track the global rollout of its optical blood pressure monitoring ecosystem. Moreover, these advancements directly tackle user adherence issues, as noted by MedCloudInsider in 2025, which reported that clinical studies found 91% of patients with uncontrolled hypertension preferred cuffless, smartphone-integrated systems over traditional monitoring approaches.
Market Challenge
The central obstacle hindering market progress is the strict requirement for clinical accuracy and regulatory standardization. Although sensor technology has evolved, securing medical-grade certification continues to be a difficult challenge. Healthcare providers and regulatory agencies demand robust evidence that these devices can provide precise readings that align with intra-arterial or standard auscultatory methods under diverse conditions. Failing to achieve this validation keeps these monitors from evolving beyond consumer wellness novelties into legitimate medical devices appropriate for diagnosing or managing hypertension.
This absence of certified reliability significantly limits adoption within clinical environments. According to the American Heart Association in 2025, approximately 80% of globally available blood pressure measurement devices lacked published data from formal validation testing, a gap that is particularly acute among cuffless technologies due to the lack of standardized testing protocols. Consequently, the failure to meet these established precision benchmarks inhibits widespread confidence among physicians, effectively excluding these products from the core healthcare market and confining their revenue potential to the less regulated direct-to-consumer wellness segment.
Market Trends
The incorporation of artificial intelligence is fundamentally transforming the market by improving the signal fidelity of optical sensors to achieve medical-grade standards. Manufacturers are increasingly utilizing sophisticated machine learning algorithms to separate clean photoplethysmography data from motion artifacts and environmental interference, thereby addressing the historical accuracy limitations of cuffless technologies. This technological progress is confirming the effectiveness of software-driven solutions; for example, Binah.ai reported in March 2025, within their "Blood Pressure Accuracy Report of SDK 5.9.1," that their AI-enhanced scanning technology attained systolic blood pressure measurement accuracy within the target error margin in 87.9% of instances, proving its suitability for reliable remote health evaluations.
At the same time, the industry is observing a distinct move toward smart rings and hearables as the preferred form factors for continuous, passive monitoring. These compact devices provide better skin contact and user comfort relative to smartwatches, facilitating consistent longitudinal data gathering without interrupting daily routines. This shift is being hastened by leading industry players actively pursuing regulatory-compliant ring-based innovations. As reported by MedTech Dive in October 2025, in the article "Oura to pursue FDA clearance of blood pressure feature for smart ring," Oura Health received approval to initiate a validation study for a new feature designed to detect physiological markers of chronic hypertension, representing a major stride toward commercializing unobtrusive ring-based management tools.
Report Scope
In this report, the Global Cuffless Blood Pressure Monitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Cuffless Blood Pressure Monitor Market.
Global Cuffless Blood Pressure Monitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: